CRISPR Therapeutics and Summit Therapeutics: Investment Outlook for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: Fool
- CRISPR Drug Progress: CRISPR Therapeutics is advancing its candidates CTX310, CTX320, and SRSD107, with CTX310 potentially lowering LDL cholesterol and triglycerides for over 40 million U.S. patients through a single treatment, thereby reducing cardiovascular event risks and enhancing market competitiveness.
- Casgevy Commercial Outlook: CRISPR expects strong commercial progress for its only approved product, Casgevy, this year, and combined with clinical advancements, it could drive stock price upward, attracting risk-tolerant investors.
- Summit's ivonescimab Potential: Summit Therapeutics' ivonescimab has outperformed Keytruda in clinical trials in China, and if approved in the U.S., it could present significant commercial opportunities, particularly in the non-small cell lung cancer market.
- Market Opportunities and Risks: While both CRISPR and Summit show strong potential in the biotech sector, they face challenges such as high treatment costs and the risk of clinical trial failures, necessitating cautious evaluation by investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 68.88 USD with a low forecast of 40.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
11 Buy
7 Hold
0 Sell
Moderate Buy
Current: 54.260
Low
40.00
Averages
68.88
High
105.00
Current: 54.260
Low
40.00
Averages
68.88
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Focuses on Earnings and Commodity Prices
- Earnings Impact: Meta's strong sales forecast and $100 billion AI investment plan drove its stock up in after-hours trading, while Microsoft fell due to slowing cloud growth and soft margin guidance, indicating a divergence in market sentiment towards tech stocks.
- Commodity Market Fluctuations: Gold prices nearing $5600 and silver surpassing $120 reflect investors' demand for safe-haven assets amid economic uncertainty, simultaneously boosting trading volumes in related ETFs like GLD and SLV.
- Market Sentiment: Despite Nasdaq and S&P 500 futures rising by 0.4% and 0.3% respectively, retail sentiment towards SPY and QQQ remains extremely bearish, suggesting ongoing investor concerns about market outlook.
- Upcoming Earnings Reports: Investors are keenly awaiting Apple's earnings report, particularly for insights on iPhone demand and AI roadmap updates, while Western Digital and SanDisk are also set to report today, potentially impacting the data storage sector.
Continue Reading
CRISPR Therapeutics Faces Renewed Pressure Amid Insider Sales
- Insider Selling Impact: CEO Samarth Kulkarni sold over 90,000 shares over three days last week, unsettling investors despite retaining approximately 85,000 shares, leading to a stock price drop of over 10%.
- Weak Revenue Growth: The company reported only $890,000 in revenue for Q3, significantly below the consensus estimate of $8.06 million, which further eroded investor confidence and negatively impacted stock performance.
- Momentum Score Decline: CRISPR's momentum score in Benzinga's stock rankings fell from 76.81 to 50.97, indicating poor price trends and volatility across multiple time frames, reflecting unfavorable short- and medium-term price movements.
- Fund Holding Changes: Frequently featured in Cathie Wood's funds, CRISPR's declining momentum score may lead to reduced confidence among investors, potentially affecting its holdings in these funds.
Continue Reading